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Summary  
Objective: Discontinuation of dopamine agonist (DA) treatment in women with prolactinoma after 
menopause is a potential approach; studies systematically assessing long-term outcomes are lacking. 
Our aim was to investigate the natural history of prolactinoma in this group.  
Design/Patients: Retrospective cohort study of women with prolactinoma diagnosed before 
menopause and who after menopause were not on DA.  
Results: Thirty women were included. Twenty-eight received DA (median duration 18 years, median 
age at DA withdrawal 52 years). At last assessment (median follow-up 3 years) and compared with 
values 6-12 months after stopping DA, PRL increased in 15%, decreased but not normalized in 33% 
and was normal in 52%; PRL levels or visible adenoma on imaging before DA withdrawal, treatment 
duration and presence of macro-/microadenoma at diagnosis were not predictors of 
normoprolactinaemia at last review, whereas PRL values 6-12 months after stopping DA were. 
Adenoma regrowth was detected in 2/27 patients (7%), who showed gradual increase of PRL. 
Comparison with 28 women who had DA withdrawal before their menopause revealed lower risk of 
hyperprolactinaemia recurrence in the postmenopausal group (HR:0.316, 95% CI:0.101-0.985, 
p<0.05). Two women with microprolactinoma diagnosed in peri-menopausal period had not been 
offered DA; PRL decreased (but not normalized) during observation of 1 and 8 years. 
Conclusions: PRL normalised over time in nearly half of the women and serum PRL 6-12 months 
after DA withdrawal is useful predictor. Nonetheless, 7% of the patients demonstrated adenoma 
regrowth which, given the life expectancy post-menopause, necessitate regular monitoring of the 
cases with persistent hyperprolactinaemia. 
 
Keywords: Prolactinoma, menopause, dopamine agonists, prolactin 
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Introduction  
Prolactinomas are the most common pituitary adenomas and are most frequently diagnosed in women 
of reproductive age (median 30.5-32 years)1-3. Dopamine agonists (DA) are the first line treatment for 
patients with symptomatic tumours, aiming to lower prolactin (PRL), reduce adenoma size and restore 
gonadal function4. Established consensus on the optimal duration of DA therapy is lacking; the 
Endocrine Society USA suggests that treatment may be tapered and perhaps withdrawn in patients 
who have normal PRL and no evidence of tumour on MRI and have received DA treatment for at 
least two years4. Nevertheless, the probability of maintenance of remission is low with a meta-
analysis showing persisting normoprolactinaemia after DA withdrawal in 21% of micro- and 16% of 
macroprolactinomas5; notably, the recurrences are most likely to occur within a year after stopping 
DA therapy6,7.   
The Endocrine Society USA guidelines also advise consideration of discontinuation of DA therapy in 
women with microprolactinoma when menopause occurs, with continuing surveillance4. This 
approach seems desirable, particularly given the issues relating with long-term compliance, costs and 
potential side effects of medical treatment. It should be noted, however, that the natural evolution of 
prolactinomas after menopause, a physiological state of oestrogen deficiency, has not been fully 
elucidated and there is indeed a scarcity of reports observing females with pre-existing prolactinoma 
beyond the menopause without continued use of DA therapy.  
Experiments in rats have shown that oophorectomy results in reduction of the size and number of 
lactotrophs and of the intracellular abundance of PRL-secretory granules8 and that selective anti-
oestrogen treatment inhibits lactotroph tumour growth in rats harbouring subcutaneously implanted 
PRL-secreting pituitary tumours9. Touraine et al.10 reported spontaneous reduction in PRL levels after 
menopause in four women with hyperprolactinaemia most likely attributed to prolactinoma. 
Karunkaran et al.11 in a group of 11 females with microprolactinoma followed through menopause 
without DA treatment, reported normalization of PRL in 45% of them; however, the duration of 
follow-up and the outcomes of those who remained hyperprolactinaemic are not available. Therefore, 
studies systematically assessing this group of patients and providing long-term outcomes and 
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frequency of adenoma regrowth would be of value in clinical practice and would facilitate the 
establishment of optimal management protocols.  
The aim of the present study was to investigate the natural history of prolactinoma in a series of 
women who have gone through menopause, who were no longer on DA therapy and were followed up 
in a large pituitary centre in the UK and to compare the risk of recurrence of hyperprolactinaemia of 
this group of patients with that of females with prolactinoma who had a trial of DA withdrawal before 
their menopause.  
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Patients and Methods 
Patients  
All women with the diagnosis of prolactinoma established before menopause and who after 
menopause were off DA treatment and were followed up in the Department of Endocrinology, Queen 
Elizabeth Hospital Birmingham, UK during the period between 2000 and 2017 were studied. As a 
control group, we used females with prolactinoma who discontinued DA treatment before menopause 
and were followed up in our Department during the same time period. The patients were identified 
through searches by the University Hospitals Birmingham IT Services in the electronic patient record, 
as well as through searching the Departmental database. The diagnosis of prolactinoma was based on 
the detection of hyperprolactinaemia (after excluding the presence of macroprolactin and potential 
secondary causes of high PRL) combined with evidence of an adenoma on pituitary imaging; in 
patients offered DA therapy, it was further supported by tumour shrinkage during follow-up. 
Menopause was confirmed by permanent cessation of menstrual periods and elevated gonadotrophins. 
Clinical, biochemical and imaging findings, medications at presentation and follow-up, and 
information on the outcomes of the patients were collected. The decision to stop DA treatment relied 
mainly on physician’s and/or patient’s preference. Serum PRL was subsequently checked at regular 
intervals and pituitary imaging was performed if PRL values showed gradual increase.  
The study was completely retrospective in nature and involved no intervention beyond routine patient 
care. It was registered with and approved as an audit by the University Hospitals Birmingham NHS 
Foundation Trust.   
Prolactin assay 
Serum PRL was measured between 2000 and 2006 by a Bayer Advia Centaur immunometric assay 
(reference range for both assays: males 40-360 mIU/L; females 60-620 mIU/L), and between 2006-
present by an E170 Roche Diagnostics immunometric assay (reference range: males 85-325 mIU/L; 
females 100-500 mIU/L). Both assays were standardised to IRP 84/500. PRL measurements with 
different assays or performed in different laboratories were not used in this study.  
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Statistics 
Percentages were calculated for categorical data and medians with ranges for continuous variables. 
Cox regression analysis was used to assess the effect of various factors on achieving normal PRL in 
post-menopausal women and on recurrence of hyperprolactinaemia in the groups of patients; Hazard 
Ratios (HR) with 95% confidence intervals (CI) were estimated.  The level of significance was set at 
p<0.05. Statistical analyses were performed by IBM SPSS Statistics for Windows, Version 22.0. 
Armonk, NY: IBM Corp.  
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Results  
Study population 
i) Group of women who stopped DA treatment after menopause   
We identified 50 women diagnosed with a prolactinoma before menopause and who had completed 
menopause before the time of last follow-up. A flowchart demonstrating the identification of the study 
population is shown in Figure 1. Amongst the patients from this original group, at last review, 16 
were still on DA, whereas 34 were not on medical treatment. In the latter group, 4 patients had 
stopped the DA at least 8 years before menopause and were not included. For the remaining 30 
women finally included, the median age at  diagnosis of the prolactinoma was 34 years (range 16-49); 
two patients with microprolactinoma diagnosed in the peri-menopausal period had not been offered 
DA treatment and the remaining 28 (22 with micro- and 6 with macroadenoma) had received DA 
[median duration of treatment 18 years (range 3-34), 10 on bromocriptine (median dose 1.25 mg/day, 
range 1.25-5 mg/day) and 18 on cabergoline (median dose 0.5 mg/week, range 0.25-1 mg/week)] 
which had been stopped after menopause (at a median age of 52 years).  In this group, 17/28 patients 
had visible adenoma on imaging before stopping DA. Median follow-up was 3 years (range 1-13) and 
was determined from the time of stopping the DA (or from the time of menopause in the two patients 
not offered DA) until the last serum PRL measurement.  
ii) Group of women who stopped DA treatment before menopause  
We identified 28 women with prolactinoma who had a trial of DA withdrawal before menopause. 
Their median age at diagnosis of the prolactinoma was 26 years (range 16-42), 23 had microadenoma 
and 5 macroadenoma, and they had received DA treatment for a median duration of 6 years (range 1-
24; one of these patients had been on DA for one year and had chosen to stop it after achieving 
normal PRL) [5 on bromocriptine (median dose 2.5 mg/day, range 2.5-5 mg/day), 21 on cabergoline 
(median dose 0.25 mg/week, range 0.25-1 mg/week) and 2 initially on bromocriptine followed by 
cabergoline]. All had normal PRL and 14/25 had visible adenoma on imaging prior stopping DA. 
Median follow-up was 1 year (range 0.1-12 years) defined from the time of stopping DA until time of 
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detection of recurrence of hyperprolactinaemia or of last PRL measurement if this had remained 
normal.  
Outcomes in women who stopped DA treatment after menopause   
 
i) Post-menopausal changes in serum PRL levels 
Prior to stopping the DA, serum PRL was normal in 16 and above the reference range in 12 patients 
(Table 1). Amongst those with normal PRL before stopping the DA, at their last review, PRL 
increased above the reference range in 5/16 (31%) and remained normal in 11/16 (69%). Of those 
with PRL above the reference range before stopping the DA, PRL had increased further in 8/12 
(67%), decreased but did not normalize in 1/12 (8%), and normalized in 3/12 (25%) (Table 1). 
Overall, at last assessment of the total group, PRL demonstrated increase (with values above the 
reference range) in 13/28 (46%), decreased but did not normalize in 1/28 (4%), and was normal in 
14/28 (50%) of the patients (Figure 2).  
PRL checked between 6 and 12 months after stopping DA was normal in 9 and above the reference 
range in 19 patients (Table 2). Amongst those with normal PRL, PRL remained within normal limits 
in all, 9/9 (100%) at their last review. Of those with high PRL 6-12 months off DA, the last recorded 
review revealed that PRL had increased further in 4/18 (22%), decreased but did not normalize in 9/18 
(50%) and normalized in 5/18 (28%) (Table 2). Overall, at last assessment of this group, PRL showed 
increase (with values above the reference range) in 4/27 (15%), decreased but did not normalize in 
9/27 (33%) and was normal in 14/27 (52%) of the women (one patient was excluded from these 
evaluations because she restarted DA within one year after the rise of the PRL) (Figure 2). Details and 
outcomes of the 4 patients who had further increase in serum PRL after stopping DA therapy are 
shown in Table 3.  
Univariate Cox regression analysis revealed that PRL levels or visible adenoma on imaging before 
stopping the DA, duration of treatment with DA, type of DA, and size of the tumour at diagnosis 
(macro- or microadenoma) were not predictors of having normal PRL at last assessment, whereas 
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PRL values within 6-12 months after stopping DA were (HR 0.996 per mU/L, 95% CI 0.004-0.999, 
p<0.05).  
In the two patients with microprolactinoma diagnosed in the peri-menopausal period who had not 
been offered DA, serum PRL did not normalize, but decreased by 70% and 27% during observation 
periods of 1 and 8 years, respectively. In these patients, the lack of confirmation of prolactinoma 
diagnosis by demonstrating tumour shrinkage by DA treatment is a potential drawback; however, 
their basal PRL levels were 2920 and 1683 mU/L after having excluded secondary causes of 
hyperprolactinaemia. 
In the total series of 30 patients, at last assessment 16 (53%) were hyperprolactinaemic.   
ii) Prolactinoma growth  
During the follow-up period, regrowth of the adenoma was detected in two patients (2/27, 7%) (Table 
3). This was not associated with pressure effects. Both had microadenomas and had shown continuous 
gradual increase in their PRL levels (before stopping DA: 1893 and 2500 mU/L – at last review: 6121 
and 4281 mU/L, respectively). After discussion with the patients, they were subsequently 
recommenced on DA. 
Recurrence of hyperprolactinaemia after DA withdrawal: comparison between pre- and 
postmenopausal women  
In the group of premenopausal women, 8/28 (29%) remained normoprolactinaemic and 20/28 (71%) 
had recurrence of hyperprolactinaemia at a median interval of 0.7 years (range 0.1-4.2) after DA 
withdrawal. 
Using this group of patients and the post-menopausal females with normal PRL prior stopping DA in 
a Cox Regression model, it was found that after adjusting for size of the tumour at diagnosis (macro- 
or microadenoma), visible adenoma on imaging before stopping the DA and duration of treatment 
with DA, recurrence of hyperprolactinaemia was lower in the post-menopausal group (HR 0.316, 95% 
CI 0.101-0.985, p<0.05).    
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Discussion  
This is the first series systematically reviewing the outcomes of females with prolactinoma who after 
reaching menopause had their DA treatment actively withdrawn. We found that during a median 
follow-up period of 3 years, 53% of the total patients had hyperprolactinaemia. In those previously 
treated with DA, this rate was 50%, with serum PRL within 6-12 months after stopping treatment 
being the only independent predictor. Interestingly, in 15% of the women, PRL showed an increase as 
compared to the levels measured between 6 and 12 months after DA withdrawal and two of these 
patients had adenoma regrowth. Our results suggest that despite the concept that menopause facilitates 
the remission of hyperprolactinaemia in women with prolactinoma, progress of the tumour is possible, 
as seen in 2 of our 30 patients, necessitating regular monitoring. 
Previous published literature on this topic is very limited and has not elucidated the behaviour of the 
prolactinoma in the long term. Thus, Karunkaran et al.11 in a retrospective study of 11 females with 
microprolactinoma diagnosed before and followed through menopause, reported that in five of them 
PRL normalised after the cessation of menses; in this group, only two had been previously treated 
with DA. It should be noted, however, that information on the time of assessment of PRL in relation 
to menopause, data on the outcomes of those who remained hyperprolactinaemic, and the duration of 
follow-up after the cessation of menses were not provided. Touraine et al.10 reported that in a small 
group of four females with hyperprolactinaemia most likely attributed to prolactinoma who did not 
receive any treatment once menopause was diagnosed, PRL levels decreased spontaneously in all [at 
onset of menopause: median 39.8 ng/ml (range 19-110) – during menopause: median 33.0 ng/ml 
(range 3-90)] during follow-up ranging between 66 and 155 months. 
In our study, the outcomes of women who had actively withdrawn DA treatment before or after 
menopause and were followed-up during the same time period in our Department were compared. 
Given that all premenopausal women had normal PRL prior stopping DA, the comparison was 
performed with the group of postmenopausal females who before DA withdrawal had also normal 
PRL. We found recurrence of hyperprolactinaemia in 31% of the postmenopausal and in 71% of the 
premenopausal group. After adjusting for possible confounding factors including size of adenoma at 
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diagnosis, duration of DA treatment and visible adenoma on imaging prior DA withdrawal, we found 
that the risk of hyperprolactinaemia recurrence was lower in the postmenopausal group suggesting a 
favourable impact of menopause. Similar data comparing directly these two groups of women are not 
available and the published literature on DA withdrawal outcomes involves patients of both sexes and 
of any age. Thus, in a meta-analysis of studies including mainly females before menopause, the rates 
of persisting normoprolactinaemia after withdrawal of DA were only 21% (95% CI, 10-37%) for 
micro- and 16% (95% CI, 6-36%) for macroprolactinomas, with longer DA treatment duration 
associated with treatment success5. In a meta-analysis of reports including only patients treated with 
cabergoline, most of which were premenopausal females, the hyperprolactinaemia recurrence rate was 
65% (95% CI 55-74%)12. 
In comparison with the PRL values detected between 6 and 12 months after DA withdrawal, PRL 
decreased but remained elevated above the reference range in 33% and normalised in 52% of our 
patients. Although this may reflect the natural course of the tumour or the cytocidal effect of the 
previous DA treatment13, the reduction of oestrogen levels following menopause could also relate to 
this observation. In fact, experimental data on rats have shown that ovariectomy has a dramatic effect 
on the lactotroph cells with a decrease in their size and number, as well as a reduction in the 
intracellular abundance of PRL secretory granules; oestradiol is the dominant ovarian hormone that 
reverses these effects and subsequently stimulates PRL secretion8. We also found that PRL values 
within 6-12 months after stopping the DA were the only predictors of tumour secretory dynamics and 
normoprolactinaemia at last assessment providing guidance on the intensity of future surveillance and 
the selection of cases for possible discharge to primary care. Notably, in studies looking at predictive 
factors of persisting normoprolactinaemia after DA withdrawal, tumour remnant prior to DA 
withdrawal, longer duration of DA treatment and nadir PRL during treatment were the most 
commonly reported5-7,14; however, these data were derived from patient groups comprising both men 
and women and a wide range of ages.  
Interestingly, at last assessment and, in comparison with the PRL levels detected 6-12 months after 
stopping DA treatment, PRL showed increase (with values above the reference range) in 4/27 (15%) 
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of the patients (all had microadenomas at diagnosis). It is of note, that this was observed in women 
with high PRL levels (>2500 mU/L) measured 6-12 months after DA withdrawal (range of PRL of 
this group in our series 2633-4270 mU/L). During the follow-up period, regrowth of the adenoma was 
detected in two of them (7% of the total group), four and six years, after stopping the DA. Whether 
the rate of adenoma regrowth would be higher if our series included more macroprolactinomas or if 
the follow-up was longer remains a possibility. These findings demonstrate that the growth potential 
of the prolactinomas remains even after menopause. In accord with this is the observation that 94% of 
the prolactinomas diagnosed after menopause are macroadenomas15. Furthermore, the long interval 
until detection of tumour regrowth signifies the importance of prolonged monitoring in cases with 
persistent hyperprolactinaemia.  
It has been previously shown that the PRL levels correlate with inflammatory biomarkers16 and that 
patients with untreated prolactinoma have metabolic disorders (including insulin resistance and 
dyslipidaemia) and an adverse cardiovascular risk profile17-20. The significance of these findings and 
their potential consequences for the group of post-menopausal women with hyperprolactinaemia after 
DA withdrawal remain to be clarified. 
A drawback of our study is the potential selection bias related to the decision on cessation DA 
treatment. A prospective series of non-selected, consecutive patients, who after menopause stop their 
DA therapy, could overcome this problem, but such a study may not be practically feasible. 
Furthermore, pituitary imaging was performed only in patients with gradual increase of serum PRL 
after treatment withdrawal. Nonetheless, given that in most of the cases PRL serves as a good marker 
of tumour behaviour21, it is unlikely that patients with adenoma regrowth may have been missed. 
Advantages of our study are the inclusion of subjects with systematic follow-up in the era of MRI 
with PRL measurements in a single laboratory (including routine macroprolactin screening) during 
the monitoring after DA withdrawal, and the use of a comparison group of females who stopped DA 
treatment before their menopause. 
In conclusion, serum PRL normalises over time in nearly half of the women with prolactinoma who 
pass through menopause and are not on DA treatment; serum PRL 6-12 months after DA withdrawal 
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is a useful predictor for this and can guide clinical practice. The risk of recurrence of 
hyperprolactinaemia is lower in this group compared with premenopausal women who had a trial of 
DA withdrawal. Nonetheless, menopause is not a sufficient condition to ensure remission of the 
tumour; during our follow-up period, 7% of the total group demonstrated adenoma regrowth which, 
given the long life expectancy after menopause, necessitates regular monitoring of the cases with 
persistent hyperprolactinaemia. The potential long-term consequences of the untreated 
hyperprolactinaemia and studies with longer follow-up on this group of patients will provide further 
insights on the field. 
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Table 1. Details and outcomes of patients who stopped dopamine agonist (DA) treatment. 
Hyperprolactinaemia just 
before stopping DA 
 
   
 PRL higher  
at last follow-up 
PRL lower but not normal  
at last follow-up 
 
PRL normal  
at last follow-up 
 
n=12* 
 
PRL (median, range) 
1193 mU/L (603-2500) 
 
Adenoma visible on 
imaging before stopping DA 
n=9/12 
 
 
n=8/12** (67%) 
 
PRL (median, range) 
2644 mU/L (1000-6121) 
 
Adenoma visible on imaging 
before stopping DA 
n=6/8 
 
 
n=1/12 (8%) 
 
PRL 
550 mU/L 
 
Adenoma visible on imaging 
before stopping DA  
n=0/1 
 
n=3/12 (25%) 
 
 
 
 
Adenoma visible on imaging 
before stopping DA  
n=3/3 
PRL normal just before 
stopping DA 
 
   
 Hyperprolactinaemia 
at last follow-up 
 
 PRL normal 
at last follow-up 
 
n=16 
 
 
 
 
 
Adenoma visible on 
imaging before stopping DA 
n=8/16 
 
n=5/16 (31%) 
 
 
PRL (median, range) 
1025 mU/L (806-1088) 
 
Adenoma visible on imaging 
before stopping DA  
n=2/5 
 
 
 
 
 
 
 
 
n=11/16 (69%) 
 
 
 
 
 
Adenoma visible on imaging 
before stopping DA  
n=6/11 
*In this group: one patient was on citalopram (PRL 1893 mU/L); one patient on oestrogen treatment and on 
amitriptyline (PRL 1057 mU/L); one patient had compliance issues.  
**One patient on amitriptyline (PRL 5622 mU/L) on which she was also even before stopping the DA. 
As imaging before stopping the DA was used the available one closest to the time of cessation of the DA 
treatment (median interval 1 year). 
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Table 2. Details and outcomes of patients based on PRL levels 6-12 months after stopping dopamine 
agonist (DA) treatment. 
Hyperprolactinaemia 
within 6-12 months after 
stopping DA 
 
   
 PRL higher  
at last follow-up 
PRL lower but not normal  
at last follow-up 
 
PRL normal  
at last follow-up 
 
n=19^ 
 
PRL (median, range) 
908 mU/L (680-4270) 
 
Adenoma visible on 
imaging before stopping DA 
n=10/19 
 
n=4/18*^ (22%) 
 
PRL (median, range) 
4957 mU/L (3440-6121) 
 
Adenoma visible on  
imaging before stopping DA  
n=2/4 
 
n=9/18* (50%) 
 
PRL (median, range) 
1046 mU/L (550-1848) 
 
Adenoma visible on imaging 
before stopping DA  
n=5/9 
 
n=5/18* (28%) 
 
 
 
 
Adenoma visible on imaging 
before stopping DA  
n=3/5 
Normal PRL within 6-12 
months after stopping DA 
 
   
 Hyperprolactinaemia 
at last follow-up 
 
 PRL normal 
at last follow-up 
 
n=9 
 
Adenoma visible on 
imaging before stopping DA 
n=7/9  
-  
 
 
 
 
 
 
n=9/9 (100%) 
 
Adenoma visible on imaging 
before stopping DA  
n=7/9  
 
*One patient was excluded because she restarted DA shortly after the first PRL measurement.  
^ One patient on amitriptyline (PRL 5622 mU/L) on which she was also even before stopping the DA treatment. 
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Table 3. Details and outcomes of the patients who had further increase in the PRL values compared 
with those detected 6-12 months after stopping dopamine agonist (DA) treatment. 
Patient PRL 
within 6-
12 months 
after 
stopping 
DA 
(mU/L) 
PRL at 
last 
follow-
up 
(mU/L) 
Adenoma size 
at diagnosis 
Residual 
adenoma 
on MRI 
before 
stopping 
DA 
Follow-
up after 
stopping 
DA 
(years) 
Findings of 
latest pituitary 
MRI 
Outcome 
1 4270 6121 Microadenoma Yes 6 Increase in size 
(of around 2 mm) 
of residual 
adenoma  
Restarted 
cabergoline with 
PRL gradually 
decreasing – 
repeat MRI 
showed reduction 
in adenoma size 
2 3280 3440 Microadenoma No 4 No MRI given 
the no substantial 
increase of PRL 
values 
Under surveillance 
3* 3149 5622 Microadenoma Yes 6 Stable 
appearances of 
the residual 
adenoma 
Under surveillance 
4 2633 4281 Microadenoma No 4 Regrowth of the 
adenoma 
(measuring 
around 4 mm) 
Restarted 
cabergoline – PRL 
decreasing - awaits 
pituitary MRI 
*On stable dose of amitriptyline during all follow-up period. 
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Figure legends 
 
Figure 1: Flowchart showing the identification of the study population. The characterisation of the 
tumour as micro- or macroadenoma relied at time of prolactinoma diagnosis. DA: dopamine agonist. 
 
Figure 2. Serum PRL values for each individual patient just before stopping dopamine agonist (DA) 
treatment, within 1 year after stopping DA and at last assessment: (A) Patients with 
microprolactinoma at diagnosis, (B) Patients with macroprolactinoma at diagnosis. The values of last 
measurement are also shown at the top of the relevant column.  
 
 
